Mounjaro (Tirzepatide): What It Is, Price & Results (2026)

Mounjaro is Eli Lilly's brand of tirzepatide, a once-weekly injection that activates both the GLP-1 and GIP hormone receptors. The FDA approved it in May 2022 to improve blood sugar in adults with type 2 diabetes, alongside diet and exercise. Lilly now labels it for type 2 diabetes in people aged 10 and older and for reducing the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes at high cardiovascular risk (lilly.com). It is not approved for weight loss on its own; the same molecule is sold for weight management as Zepbound.

Mounjaro's list price is $1,112 per month at every dose (Eli Lilly, pricinginfo.lilly.com). Self-pay through Lilly's LillyDirect pharmacy starts at $499/month for every dose from 2.5 mg to 15 mg. With commercial insurance that covers it, the Mounjaro Savings Card can bring a 1-, 2- or 3-month fill to as little as $25; with commercial insurance that does not cover it, the card brings it to as low as $499/month. The card excludes Medicare and Medicaid and expires December 31, 2026.

Without insurance Mounjaro costs about $1,112 a month at list price, or from $499/month self-pay through LillyDirect with a prescription. The $25 savings card offer requires commercial coverage for Mounjaro. Cash-pay patients using tirzepatide for weight loss often compare it with brand Zepbound on LillyDirect ($299–$449/month) or compounded tirzepatide ($119–$399/month among tracked providers, not FDA-approved).

Mounjaro is FDA-approved for type 2 diabetes, so prescribing it purely for weight loss is off-label and insurers rarely cover that use. People with type 2 diabetes do lose weight on it: in SURMOUNT-2 (Lancet 2023) adults with obesity and type 2 diabetes lost 12.8% of body weight on 10 mg and 14.7% on 15 mg over 72 weeks, against 3.2% on placebo. For weight management without diabetes, the FDA-approved tirzepatide brand is Zepbound.

Mounjaro and Zepbound contain the same molecule, tirzepatide, made by Eli Lilly, in the same weekly doses (2.5 mg to 15 mg). Mounjaro is approved for type 2 diabetes; Zepbound was approved in November 2023 for chronic weight management and later for obstructive sleep apnea with obesity. They differ in insurance coverage and price: $1,112 vs $1,086 list, and $499 vs $299–$449 a month on LillyDirect.

In the SURPASS-2 head-to-head trial (NEJM 2021) in 1,879 adults with type 2 diabetes, Mounjaro lowered A1C by 2.01 to 2.3 percentage points and body weight by 7.6 to 11.2 kg over 40 weeks, against 1.86 points and 5.7 kg for Ozempic (semaglutide 1 mg). Ozempic has a longer cardiovascular-outcomes record and a lower list price ($998 a month). Which is better for you depends on your A1C, weight goals, coverage and tolerance.

You need a prescription for an approved use, usually type 2 diabetes, from your own doctor, an endocrinologist or a diabetes telehealth service. It can be filled at a retail pharmacy (with insurance and the savings card if eligible) or through LillyDirect, Lilly's own pharmacy, which ships the single-dose pens to your home or arranges pickup and starts at $499/month self-pay. Medicare Part D plans may cover Mounjaro for type 2 diabetes under their own formulary; Mounjaro is not part of the Medicare GLP-1 Bridge.

Mounjaro starts at 2.5 mg once a week for four weeks, then increases by 2.5 mg at least every four weeks as needed for blood-sugar control, up to a maximum of 15 mg weekly. The 2.5 mg starting dose is for tolerability, not glucose control. It is injected under the skin of the stomach, thigh or upper arm on the same day each week using a single-dose pen.

The most common side effects are gastrointestinal. In the FDA label's pooled placebo-controlled trials, nausea affected 12–18% of people depending on dose, diarrhea 12–17%, vomiting 5–9% and constipation 6–7%, mostly mild and worst after dose increases. Mounjaro carries an FDA boxed warning for thyroid C-cell tumors seen in rodents and must not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Taken with insulin or a sulfonylurea it can cause low blood sugar.

Compounded tirzepatide uses the same active ingredient but is not Mounjaro: it is prepared by a licensed compounding pharmacy for an individual prescription and is not an FDA-approved finished product, so the FDA has not reviewed it for safety, effectiveness or quality. It costs less, $119/month at the low end from Embody and SnagRx in our data, against $499/month self-pay for brand Mounjaro.